Chordate Medical Holding AB Logo

Chordate Medical Holding AB

Develops a patented, drug-free neuromodulation treatment for migraine and rhinitis.

CMH | ST

Overview

Corporate Details

ISIN(s):
SE0021486131 (+1 more)
LEI:
549300R0GG2J3S0BFN79
Country:
Sweden
Address:
C/O Regus, 164 40 Kista

Description

Chordate Medical Holding AB is a medical technology company that has developed and patented Ozilia®, a CE-marked, drug-free neuromodulation treatment. The technology is indicated for the treatment of chronic migraine and chronic rhinitis. Ozilia® provides a non-pharmacological alternative to conventional medications, such as pills or injections, and is associated with minimal side effects. The company's business model is centered on building value through an extensive patent portfolio, clinical studies demonstrating efficacy, and establishing commercial success in selected markets with the goal of a future exit.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chordate Medical Holding AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chordate Medical Holding AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chordate Medical Holding AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-14 Tommy Hedberg Other Other 2,917 11,668.00 SEK
2024-03-26 Anders Weilandt Other Buy 800,000 41,440.00 SEK
2024-03-26 Anders Weilandt Other Buy 200,000 10,540.00 SEK
2023-05-26 Anders Weilandt Other Buy 2,000,000 84,000.00 SEK
2023-05-26 Jan Hermansson Other Buy 750,000 31,500.00 SEK
2023-05-26 Nils Henrik Milton Rammer Other Other 350,000 14,700.00 SEK
2023-05-26 Caroline Brandberg Other Other 225,000 9,450.00 SEK
2023-05-26 Tommy Hedberg Other Buy 225,000 9,450.00 SEK
2023-01-09 Anders Weilandt Other Buy 3 2.10 SEK
2022-02-25 Anders Weilandt Other Buy 51,292 3,949,484.00 SEK

Peer Companies

Nicox S.A. Logo
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
France
COX
NLS Pharmaceutics Ltd. Logo
Clinical-stage biopharma firm developing therapies for rare and complex CNS disorders.
United States of America
NLSP
NovoCure Ltd Logo
Develops a non-invasive cancer therapy using electric fields to disrupt solid tumors.
United States of America
NVCR
NUFORMIX PLC Logo
Pharmaceutical developer using cocrystal technology to repurpose drugs for fibrosis.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Clinical-stage biopharma developing protein degradation therapies for various diseases.
United States of America
NRIX
OLIPASS CORPORATION Logo
An R&D company developing RNA therapeutics using its proprietary OPNA platform.
South Korea
244460
A technology platform for therapeutic antibody discovery using transgenic animals.
United States of America
OABIW
ONCIMMUNE HOLDINGS PLC Logo
Immunodiagnostics company specializing in antibody and autoantibody biomarker signatures.
United Kingdom
ONC
Oncocross Co.,Ltd. Logo
An AI biotechnology firm that develops drugs by predicting drug-disease interactions.
South Korea
382150
ONCODESIGN Logo
Develops therapeutic and diagnostic solutions for resistant and metastatic cancers.
France
ALONC

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.